Nonetheless, it’s important to emphasize that further preclinical and clinical studies are imperative to comprehensively delineate the optimal therapeutic strategies, potential side effects, and long-term outcomes associated with targeting RRM2 and the associated signaling pathways in the context of prostate cancer. Here, RRM2 is linked to Familial prostate cancer.